Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials.

ABSTRACT:

Purpose

Dose-limiting neuropathy is a major adverse event associated with most of the microtubule-stabilizing agent-based chemotherapy regimens. Ixabepilone, a semisynthetic analogue of the natural epothilone B, has activity against a wide range of tumor types. Peripheral neuropathy (PN), associated with ixabepilone treatment, is usually mild to moderate, predominantly sensory and cumulative. Preclinical studies demonstrate that ixabepilone and taxanes produce a similar neurotoxicity profile.

Methods

We searched databases of phase II/III clinical trials involving patients receiving ixabepilone as a monotherapy or in combination with capecitabine for incidences of neuropathy. Potential risk factors for grade 3/4 PN were identified by a Cox regression analysis on a dataset of

SUBMITTER: Vahdat LT 

PROVIDER: S-EPMC3461204 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature